Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation

Journal of Hypertension

Volumn 24, Issue 9, 2006, Pages 1809-1816

  Janke, Jürgen ^a   Schupp, Michael ^b   Engeli, Stefan ^a   Gorzelniak, Kerstin ^a   Boschmann, Michael ^a   Sauma, Lilian ^c   Nystrom, Fredrik H ^c   Jordan, Jens ^a   Luft, Friedrich C ^a   Sharma, Arya M ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c LINKÖPING UNIVERSITY   (Sweden)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Adipogenesis; Angiotensin receptor blocker; Obesity; PPAR ; Type 2 diabetes mellitus

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; EPROSARTAN; IRBESARTAN; LIPOPROTEIN LIPASE; LOSARTAN; LUCIFERASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PLACEBO; TELMISARTAN;

ADIPOGENESIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CULTURE MEDIUM; DNA RESPONSIVE ELEMENT; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; GENE ACTIVATION; HUMAN; HUMAN CELL; MALE; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REPORTER GENE; SUBCUTANEOUS FAT; VALIDATION PROCESS;

EID: 33747438362     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000242405.68461.84     Document Type: Article

References (32)

1. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30:487-496.
2. Boschmann M, Jordan J, Adams F, Christensen NJ, Tank J, Franke G, et al. Tissue-specific response to interstitial angiotensin II in humans. Hypertension 2003; 41:37-41.
3. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107:133-139.
4. Carvalho CR, Thirone AC, Gontijo JA, Velloso LA, Saad MJ. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 1997; 46:1950-1957.
5. Katovich MJ, Pachori A. Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin. Diabetes Obes Metab 2000; 2:3-14.
6. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51:1699-1707.
7. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4:611-617.
8. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10:355-361.
9. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (Troglitazone in the prevention of diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998; 19:217-231.
10. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109:2054-2057.
11. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43:993-1002.
12. Darimont C, Vassaux G, Ailhaud G, Negrel R. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotenin II. Endocrinology 1994; 135:2030-2036.
13. Schling P, Löffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes. Horm Metab Res 2001; 33:189-195.
14. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52:942-947.
15. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54:2838-2843.
16. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 1997; 17:2166-2176.
17. Stenkula KG, Said L, Karlsson M, Thorn H, Kjolhede P, Gustavsson J, et al. Expression of a mutant IRS inhibits metabolic and mitogenic signalling of insulin in human adipocytes. Mol Cell Endocrinol 2004; 221:1-8.
18. Boschmann M, Engeli S, Adams F, Franke G, Luft FC, Sharma AM, Jordan J. Influences of AT1-receptor blockade on tissue metabolism in obese men. Am J Physiol Regul Integr Comp Physiol 2006; 290:R219-R223.
19. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005; 5:129-134.
20. Smith SA. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. Biochimie 2003; 85:1219-1230.
21. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117:385-392.
22. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42:76-81.
23. Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Acikel C, et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99:c115-c121.
24. Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K. Angiotensin-II- induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005; 48:1066-1074.
25. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52:667-674.
26. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89:4312-4319.
27. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22:1977-1982.
28. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54:3442-34452.
29. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, et al. The adipose-tissue RAAS: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35:807-825.
30. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004; 576:492-497.
31. Plosker GL, Foster RH. Eprosartan: a review of its use in the management of hypertension. Drugs 2000; 60:177-201.
32. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationships to lipoprotein lipase. J Clin Invest 1995; 95:2111-2119.